Hot Keywords
Tumor Microenvironment Exosomes and Extracellular Vesicles Breast Cancer Metastasis Bone Metastasis Metastatic Renal Cell Carcinoma Lymph node metastasis Mesothelioma Hematological Malignancies Thyroid Cancer Liquid Biopsies Early Diagnosis Lung Cancer Brain Tumors Lymphoma Oncolytic Virus Cervical Cancer Cancer Stem Cells

Topic: Metastatic Urothelial Carcinoma

A special issue of Journal of Cancer Metastasis and Treatment

ISSN 2454-2857 (Online), ISSN 2394-4722 (Print)

Submission deadline: 30 Oct 2021

Guest Editor(s)

  • Prof. Aristotelis Bamias

    Second Propaeudeutic Dept of Internal Medicine, National & Kapodistrian
    University of Athens, ATTIKON University Hospital of Athens, Athens, Greece.

    Website | E-mail

Special Issue Introduction

Urothelial cancer (UC) is a common human cancer. Although cure is achieved in the majority of patients with non-metastatic disease, the prognosis of metastatic UC (mUC) is poor with only 20% of patients achieving 3-year survival. Although platinum-based chemotherapy has been the standard of care for 40 years, significant progress has been achieved in our understanding of this disease. Validated risk models offer the opportunity of accurately predicting survival after 1st or 2nd line chemotherapy. Cisplatin-eligibility criteria can be used to select the most effective platinum compound. Staging of UC has been revised to reflect the difference in prognosis between lymph-node and visceral metastases. Recently, the concept of oligometastatic disease in UC, as an area where the addition of “radical” local therapy to systemic therapy can offer a prognostic advantage in metastatic disease, has emerged. In the therapeutic area, anti-PD1 and anti-PDL1 agents are the first to show improvement of survival after 40 years of chemotherapy “exclusiveness”. This is the combination with the introduction to molecular subtyping of UC, creating an optimism for individualized management of mUC. This special issue of the Journal of Cancer Metastasis and Treatment aims to provide a critical review on the state-of-the-art and all the recent developments in therapy and translational research in mUC.

We will welcome submissions on the following topics:
Impact of changes introduced by AJCC staging on therapy of mUC
Determinants of prognosis in mUC
The role of chemotherapy in mUC
The role of modern immunotherapy in mUC
Non-chemotherapy, non-immunotherapy novel therapies
The role of surgery in mUC
The role of radiotherapy in mUC
Oligometastatic UC
Biomarkers as a means of therapy selection in mUC
Developments in molecular characterization of UC

Submission Deadline

30 Oct 2021

Submission Information

Articles of special issue are free of charge for article processing.
For Author Instructions, please refer to
For Online Submission, please login at
Submission Deadline: 31 Oct 2021
Contacts: Olivia Zhao, Assistant Editor,

Published Articles

© 2016-2023 OAE Publishing Inc., except certain content provided by third parties